NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection

Phase 1

Withdrawn

Conditions: Communicable Diseases
Healthy

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00006630

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00006291

Locations: 🇺🇸
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States
🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸
USC CRS, Los Angeles, California, United States

and more 23 locations

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 472

Registration Number: NCT00005758

Locations: 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸
Ucsf Aids Crs, San Francisco, California, United States

and more 14 locations

Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV

Phase 2

Withdrawn

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00021762

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infections
Leukoencephalopathy, Progressive Multifocal

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT00001048

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸
Univ. of Miami AIDS CRS, Miami, Florida, United States

and more 6 locations

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

Phase 1

Completed

Conditions: HIV Infections
Pregnancy

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00001041

Locations: 🇺🇸
San Francisco Gen. Hosp., San Francisco, California, United States
🇺🇸
Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States
🇺🇸
UCSF Pediatric AIDS CRS, San Francisco, California, United States

and more 3 locations

Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 29

Registration Number: NCT00012519

Locations: 🇺🇸
Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States
🇺🇸
Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States
🇺🇸
Metropolitan Hosp. Ctr., New York, New York, United States

and more 9 locations

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

Phase 2

Completed

Conditions: HIV Wasting Syndrome
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT00001079

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States

and more 18 locations

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

Phase 3

Completed

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT00001028

Locations: 🇺🇸
Community Consortium of San Francisco, San Francisco, California, United States
🇺🇸
Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States
🇺🇸
Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States

and more 11 locations

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine

Withdrawn

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000835

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy